Thermo Fisher Scientific (NYSE:TMO) started the fiscal year on solid footing, reporting first-quarter results for 2026 that surpassed analyst expectations on both revenue and earnings. The life sciences giant posted revenue of $11.01 billion for the quarter ended March 28, 2026, a 6% increase from the $10.36 billion reported in the same period last year. This figure edged past the consensus estimate of approximately $10.96 billion.
On the bottom line, the company delivered adjusted earnings per share (EPS) of $5.44, exceeding the analyst forecast of $5.28 and marking a 6% improvement over the prior year’s adjusted EPS of $5.15. GAAP diluted EPS came in at $4.43, up 11% year-over-year.
Despite the earnings beat, the market reaction has been notably cautious. The stock is currently indicated to open roughly 4.3% lower in pre-market trading. This pullback comes after a mixed recent performance: the shares are down about 3.3% over the last week but have gained roughly 4.8% over the past month.
Recent Performance
Thermo Fisher’s first-quarter performance was driven by broad-based execution across its segments. The company highlighted several key operational achievements during the quarter:
- Revenue Growth: Total revenue rose 6% year-over-year to $11.01 billion. Organic revenue growth, which excludes the impacts of acquisitions, divestitures, and currency, came in at 1%.
- Profitability:
- GAAP operating income reached $1.86 billion, up 9% from the prior year, with a GAAP operating margin of 16.9% (versus 16.6% in Q1 2025).
- Adjusted operating income hit $2.40 billion, a 6% increase, though the adjusted operating margin slipped slightly to 21.8% from 21.9% a year ago.
- Cash Flow: Free cash flow for the quarter was $825 million, more than doubling the $373 million generated in Q1 2025, reflecting robust cash generation from operations.
- Strategic Moves: The company completed its acquisition of Clario, a provider of endpoint data solutions, and announced a strategic collaboration with NVIDIA to integrate AI into scientific instrumentation.
- Capital Deployment: Thermo Fisher repurchased $3.0 billion of its own stock during the quarter and increased its dividend by 10%.
Valuation Metrics
While the company does not trade at a bargain multiple compared to some industrial peers, its consistent earnings growth and strong free cash flow generation provide a solid foundation. The current price action suggests some investors may be locking in profits after the stock’s recent run-up, or they may be awaiting further clarity on the full-year outlook. The company did not provide an updated 2026 financial guidance in its earnings release, stating only that it would do so during its conference call. This lack of explicit forward guidance could be one factor tempering the post-earnings enthusiasm.
Analyst Views
Analysts are currently estimating Thermo Fisher’s full-year 2026 revenue at approximately $47.47 billion, with adjusted EPS of $24.81. For the upcoming second quarter, the consensus calls for revenue near $11.61 billion and EPS of roughly $5.85.
The earnings beat itself is a clear positive, but the pre-market decline indicates that expectations may have been priced in or that the market was hoping for a more bullish forward outlook. The slight compression in adjusted operating margins, even as revenue grows, might also be drawing scrutiny from analysts focused on operational efficiency.
For more historical earnings data and future projections and estimates, you can view Thermo Fisher Scientific’s full earnings history and analyst ratings at Chartmill (TMO Earnings) and Chartmill (TMO Analyst Ratings).
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.